Enanta Pharmaceuticals (ENTA) Capital Expenditures (2012 - 2025)
Enanta Pharmaceuticals (ENTA) posted Capital Expenditures of -$11.4 million for Q3 2025, down 7479.35% on a QoQ basis from $155000.0 in Q2 2025, and down 281.7% year-over-year from $6.3 million in Q3 2024.
Enanta Pharmaceuticals (ENTA) Capital Expenditures (2012 - 2025) Analysis & Trends
Enanta Pharmaceuticals' Capital Expenditures history runs 14 years deep, the most recent figure standing at -$11.4 million for Q3 2025.
- Quarterly Capital Expenditures fell 281.7% year-over-year to -$11.4 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was -$11.3 million (down 180.09% YoY) and the FY2024 annual result came in at $5.6 million, up 5130.84% from the prior year.
- Capital Expenditures was -$11.4 million for Q3 2025 at Enanta Pharmaceuticals, down from $155000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $8.9 million in Q1 2025 and bottomed at -$11.4 million in Q3 2025.
- A 5-year average of $424500.0 and a median of $196500.0 in 2022 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 9480.0% in 2023, while the deepest fall reached 542.67% in 2023.
- Enanta Pharmaceuticals' Capital Expenditures stood at $46000.0 in 2021, then plunged by 89.13% to $5000.0 in 2022, then soared by 9480.0% to $479000.0 in 2023, then soared by 406.68% to $2.4 million in 2024, then sank by 571.28% to -$11.4 million in 2025.
- Business Quant data shows ENTA's Capital Expenditures at -$11.4 million in Q3 2025, $155000.0 in Q2 2025, and $8.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -11.44 Mn |
| Sep 30, 2025 | -11.44 Mn |
| Jun 30, 2025 | 155,000.00 |
| Jun 30, 2025 | 155,000.00 |
| Mar 31, 2025 | 8.86 Mn |
| Mar 31, 2025 | 8.86 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Sep 30, 2024 | 6.30 Mn |
| Jun 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -3.49 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Dec 31, 2023 | 479,000.00 |
| Dec 31, 2023 | 479,000.00 |
| Sep 30, 2023 | -7.58 Mn |
| Sep 30, 2023 | -7.58 Mn |
| Jun 30, 2023 | 6.08 Mn |
| Jun 30, 2023 | 6.08 Mn |